FY2024 EPS Estimates for Bruker Reduced by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Bruker in a report issued on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $2.38 for the year, down from their prior forecast of $2.61. The consensus estimate for Bruker's current full-year earnings is $2.61 per share. Leerink Partnrs also issued estimates for Bruker's Q3 2025 earnings at $0.70 EPS.

BRKR has been the subject of a number of other reports. Citigroup lowered their target price on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday. Wolfe Research cut shares of Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. Barclays reduced their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a research report on Wednesday. TD Cowen decreased their price objective on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research report on Wednesday. Finally, Wells Fargo & Company dropped their target price on Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Bruker presently has an average rating of "Moderate Buy" and a consensus target price of $79.36.

Bruker Price Performance

BRKR stock traded up $1.51 during midday trading on Thursday, reaching $60.49. 1,346,609 shares of the company's stock traded hands, compared to its average volume of 1,264,657. The company has a 50-day simple moving average of $63.97 and a two-hundred day simple moving average of $66.51. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. Bruker has a 1-year low of $54.55 and a 1-year high of $94.86. The company has a market cap of $9.16 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 2.32 and a beta of 1.20.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business's quarterly revenue was up 16.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.74 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Covestor Ltd raised its stake in Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company's stock worth $34,000 after buying an additional 210 shares during the period. First Horizon Advisors Inc. boosted its holdings in shares of Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock valued at $25,000 after buying an additional 218 shares during the period. UMB Bank n.a. increased its position in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock worth $46,000 after acquiring an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in Bruker in the 2nd quarter valued at $52,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Bruker by 40.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company's stock worth $81,000 after purchasing an additional 248 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.